ClinicalTrials.gg
Not yet recruitingNCT07846176CAMPHOR-HCMUpdated Sep 29, 2026

Aficamten and Patient-Reported Outcomes in Real-World nHCM

An observational study in Hypertrophic Cardiomyopathy (HCM), sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This multicenter, prospective, observational, real-world clinical study aims to evaluate the efficacy and safety of Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) by prospectively observing changes in symptoms, biomarkers, imaging findings, and adverse reactions, etc. It will also record the dosing regimens at which individual patients achieve steady state, and explore the treatment patterns of Aficamten in Chinese patients with symptomatic nHCM.

02

Conditions studied

  • Hypertrophic Cardiomyopathy (HCM)

Keywords

  • non obstructive hypertrophic cardiomyopathy
  • aficamten
03

In context

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

This study's planned enrollment of 100 is below the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.

Browse Cardiomyopathy, Hypertrophic studies →

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-85 years.
  • Confirmed diagnosis of HCM:

    1. Left ventricular wall thickness ≥15 mm at any site on echocardiography or cardiac magnetic resonance.
    2. Left ventricular wall thickness ≥13 mm in individuals testing positive for a pathogenic variant or in genetically affected family members.
    3. Ventricular wall thickening caused by other cardiovascular diseases or systemic or metabolic disorders has been excluded.
  • Symptomatic nHCM patients meeting all of the following conditions:

    1. Left ventricular outflow tract gradient (LVOTG) \<30 mmHg at rest and/or with provocation.
    2. Presence of any one of the following symptoms: fatigue (weakness), dyspnea, chest pain, palpitations, or syncope.
    3. (NYHA) functional class II or III.
  • (LVEF) ≥60% as assessed by transthoracic echocardiography.
  • Signed and dated written , and willingness to return for clinical follow-up.

Exclusion criteria

Exclusion Criteria:

  • LVOTG ≥30 mmHg at rest and/or with provocation.
  • \<50% on transthoracic echocardiography.
  • Symptomatic hypotension or systolic blood pressure (SBP) \<100 mmHg.
  • Severe renal impairment, estimated (eGFR) \<30 mL/min/1.73 m², or currently receiving blood purification therapy.
  • Planned implantable cardioverter-defibrillator (ICD) implantation or cardiac resynchronization therapy (CRT) within 3 months.
  • Women who are pregnant or planning to become pregnant during the trial.
  • Currently participating in another device or drug trial.
  • Any other clinical condition with an expected survival of less than 2 years.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Aficamten group

    Patients with non-obstructive hypertrophic cardiomyopathy (nHCM) receiving aficamten therapy

    Drug: receiving aficamten

Interventions

  • Drugreceiving aficamten

    Aficamten will be administered at a specified dose according to each patient's tolerability, as assessed by echocardiography.

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in NT-proBNP and/or absolute change from baseline in KCCQ-CSS

    Time frame: From enrollment to the end of treatment at 24 months

Secondary outcomes

  1. Absolute change from baseline in NT-proBNP

    Time frame: From enrollment to the end of treatment at 24 months

  2. Percentage change from baseline in TnT/TnI

    Time frame: From enrollment to the end of treatment at 24 months

  3. Absolute change from baseline in TnT/TnI

    Time frame: From enrollment to the end of treatment at 24 months

  4. Absolute change from baseline in maximal wall thickness (MWT)

    Time frame: From enrollment to the end of treatment at 24 months

  5. Absolute change from baseline in E/e'

    Time frame: From enrollment to the end of treatment at 24 months

  6. Absolute change from baseline in left ventricular end-diastolic volume index (LVEDdi)

    Time frame: From enrollment to the end of treatment at 24 months

  7. Proportion of patients with improvement of ≥1 NYHA functional class

    Time frame: From enrollment to the end of treatment at 24 months

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Jun 2029, 24 months later.

Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartEst.
Jun 1, 2027
Primary completionEst.
Jun 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07846176
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Jun 1, 2027 (estimated)
Primary completion
Jun 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Xiaojie Xie, MD, PhD
Contact
xiexj@zju.edu.cn
86+571-87784700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion